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This study investigates the clinical significance of Anoctamin-1 gene mapping at 11q13 amplicon 
in both the development and progression of head and neck squamous cell carcinomas (HNSCC). 
ANO1 protein expression was evaluated by immunohistochemistry in a cohort of 372 surgically 
treated HNSCC patients and also in 35 laryngeal precancerous lesions. ANO1 gene amplification 
was determined by real-time PCR in all the laryngeal premalignancies and 60 of the HNSCCs, and 
molecular data correlated with clinical outcome. ANO1 gene amplification was frequently detected 
in both premalignant lesions (63%) and HNSCC tumours (58%), whereas concomitant ANO1 
expression occurred at a much lower frequency (20 and 22%). Interestingly, laryngeal dysplasias 
harbouring ANO1 gene amplification showed a higher risk of malignant transformation (HR = 3.62; 
95% CI 0.79–16.57; P = 0.097; Cox regression). ANO1 expression and gene amplification showed no 
significant associations with clinicopathological parameters in HNSCC. However, remarkably ANO1 
expression differentially influenced patient survival depending on the tumour site. Collectively, this 
study provides original evidence demonstrating the distinctive impact of ANO1 expression on HNSCC 
prognosis depending on the tumour site.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Despite 
major advancements in cancer diagnosis and treatment, the survival rate for patients with HNSCC has 
only marginally improved over the past few decades1. Our ability to prognosticate advanced cases of 
HNSCC is especially poor owing to variations in the biological behaviour of tumours and inadequacies of 
the present staging system. Hence, it is essential to identify new markers that can distinguish differences 
in tumour condition and augment the predictive power of the current clinical markers2.
Amplification of chromosomal region 11q13 has been described in various human carcinomas, 
including those of the head and neck, breast, oesophagus, lung, ovary and bladder (reviewed in3). This 
genetic alteration is one of the most frequently observed in HNSCC (20–52%), found to correlate with 
aggressive tumour growth, the presence of lymph node metastasis and poor prognosis4.
The core region of amplification in HNSCC has been identified, which contains multiple genes show-
ing increased expression associated to gene amplification5. Furthermore, it has been recently demon-
strated using high-resolution genomic and transcriptomic microarray analysis that the amplification 
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and expression of various genes within the 11q13 amplicon may predict the risk of developing dis-
tant metastasis in HNSCC patients6. On this basis, Anoctamin-1 gene (ANO1, also termed TMEM16A, 
ORAOV2, DOG1, TAOS2 and FLJ10261), encoding a calcium-activated chloride channel, has emerged 
as a strong candidate to drive 11q13 amplification in HNSCC by providing growth advantage to tumours 
and favouring metastatic dissemination7.
These important observations prompted us to perform a comprehensive study to investigate the clin-
ical significance of ANO1 expression and gene amplification in a large series of HNSCC tissue speci-
mens to establish ANO1 role in patient prognosis and disease outcome. Furthermore, the present study 
explores for the first time ANO1 role in early stages of HNSCC tumourigenesis and malignant transfor-
mation by analysing both ANO1 protein expression and gene amplification in laryngeal premalignant 
lesions, and also the correlations with the risk of progression to laryngeal cancer.
Results
Analysis of ANO1 protein expression and gene amplification in HNSCC. Immunohistochemical 
analysis of ANO1 expression was carried out on HNSCC TMAs composed of tissue sections from 372 
HNSCC. Each TMA also contained sections of normal epithelium as an internal control. Immunostaining 
was successfully evaluated in 357 (96%) of 372 cases. An overview of all clinicopathological data of these 
patients is given in Table 1. 78 (22%) of the 357 tumours exhibited positive ANO1 expression (Fig. 1A,B) 
showing preferentially a membranous pattern, whereas ANO1 expression was negligible in both normal 
epithelium and stromal cells (Fig. 1).
ANO1 gene amplification was investigated in 60 HNSCC tissue specimens by real-time PCR (Q-PCR). 
ANO1 gene amplification was detected in 35 (58%) tumour samples with relative copy numbers ranging 
from two- to 19-fold (median, 6.1 fold). Statistical analysis revealed a positive correlation between ANO1 
protein expression and gene amplification (Spearman’s (rho) = 0.378, P = 0.003). All tumours showing 
ANO1-positive expression harboured ANO1 gene amplification; however, gene amplification did not lead 
to increased expression in all cases.
Associations with clinicopathological parameters and disease outcome. ANO1 protein expres-
sion was correlated with clinicopathological parameters (Table 1). ANO1-positive expression was found 
at each anatomic site, although with a higher frequency in oropharyngeal and hypopharyngeal tumours 
compared to laryngeal tumours (P = 0.065). No significant associations between ANO1 expression and 
other clinicopathological parameters were observed in our patient cohort (Table 1).
Characteristic No.
ANO1-positive 
expression (%) OR (95% CI) P#
- pT classification
 T1-T2 107 28 (26) 1
0.169 T3 122 20 (16) 0.553 (0.290–1.054)
 T4 125 30 (24) 0.891 (0.491–1.616)
- pN classification
 N0 93 18 (19) 1
0.499
 N1-3 264 60 (23) 1.225 (0.680–2.210)
- Disease stage
 I–II 37 11 (30) 1
0.108 III 63 8 (13) 0.344 (0.124–0.957)
 IV 257 59 (23) 0.704 (0.329–1.510)
- Pathological grade
 Well differentiated 140 35 (25) 1
0.117 Moderately differentiated 141 23 (16) 0.585 (0.325–1.053)
 Poorly differentiated 75 20 (27) 1.091 (0.576–2.067)
- Site
 Oropharynx 240 60 (25) 1
0.065
 Hypopharynx 60 12 (20) 0.750 (0.374–1.505)
 Larynx 57 6 (11) 0.353 (0.144–0.864)
Total Cases 357 78 (22)
Table 1.  Associations between ANO1 protein expression and clinicopathological findings in HNSCC 
patients (N = 357). #P value associated to the odds ratio (OR).
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Nevertheless, ANO1 expression showed an impact on disease outcome. Multiple decrement 
Kaplan-Meier demonstrated that ANO1 expression is associated with increased disease-specific (DSS) 
and overall (OS) survival in the total cohort of 357 patients, although the differences did not reach sta-
tistical significance (Table 2).
To further confirm these results we repeated the immunohistochemical analysis of ANO1 expres-
sion using a different antibody (anti-TMEM16A antibody [SP31] from Abcam). 78 (22%) out of 350 
cases showed positive ANO1 expression and a highly significant correlation was found when comparing 
ANO1 immunostaining detected with both antibodies (Spearman’s rho 0.917, P < 0.001). Furthermore, 
analogous findings were obtained regarding the impact of ANO1 expression (with [SP31] antibody) on 
patients’ survival (Supplementary Table S1).
Given that tumour site exerts an important influence on the prognosis of HNSCC patients, the impact 
of ANO1 expression on disease course was also examined separately in each anatomic site. Important 
differences were observed on patient survival between the different subgroups. Thus, patients with 
ANO1-positive oropharyngeal tumours exhibited a significantly improved DSS and OS (Table 2); whilst 
ANO1 expression showed no influence on survival of patients with hypopharyngeal, and was associated 
with a poorer survival, although not significant, in laryngeal tumours (Table 2). These results were con-
firmed by repeating ANO1 expression analysis with [SP31] antibody (Supplementary Table S1).
Amplification of ANO1 gene did not show any significant association with clinical parameters or 
disease outcome. The 5-year DSS for non-amplified and amplified cases was 58% and 52% (HR = 1.15; 
Figure 1. Immunohistochemical analysis of ANO1 protein expression. Representative examples of head 
and neck carcinomas showing strong ANO1 staining (A), negative staining (B), and laryngeal dysplasias 
with strong ANO1 staining (C) and negative staining (D). Normal adjacent epithelia showed negligible 
ANO1 staining (E). Original magnification x200.
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95% CI 0.60–2.2; P = 0.68), and the 5-year OS for non-amplified and amplified cases was 49% and 39% 
(HR = 1.2; 95% CI 0.67–2.14; P = 0.54).
Analysis of ANO1 protein expression and gene amplification in early stages of tumourigene-
sis. ANO1 protein expression and gene amplification was evaluated on a set of 35 laryngeal premalig-
nant lesions to determine their timing and frequency during HNSCC tumourigenesis.
Positive ANO1 expression was detected in 7 (20%) out of 35 laryngeal dysplasias (Fig. 1C,D), whilst 
ANO1 gene amplification was found at a much higher frequency (63%, 22/35 laryngeal dysplasias). Clear 
differences were observed in relation to the histopathologic classification (Fig.  2). Thus, ANO1 gene 
amplification occurred very early during tumourigenesis, thereby being detected in patients with mild 
dysplasias and at a high frequency along the different stages of tumour progression (Table 3). In contrast, 
ANO1 protein expression was only detected in severe dysplasia/carcinoma in situ (CIS) and at a much 
lower frequency than gene amplification (Table 3 and Fig. 2).
Statistical analysis revealed a significant correlation between ANO1 protein expression and gene 
amplification (Spearman’s (rho) = 0.401, P = 0.019). However, even though all seven ANO1-positive 
dysplasias harboured ANO1 gene amplification, most cases with increased gene copy number showed 
ANO1-negative expression.
Patients ANO1-positive expression ANO1-negative expression HR (95% CI); P
Whole series:
 - DSS 56% 44% 0.76 (0.53- 1.08); 0.13
 - OS 47% 36% 0.75 (0.55- 1.02); 0.07
Oropharyngeal tumours
 - DSS 61% 44% 0.63 (0.41–0.98); 0.04
 - OS 49% 35% 0.68 (0.47–0.98); 0.04
Hypopharyngeal tumours
 - DSS 51% 36% 0.77 (0.36–1.67); 0.51
 - OS 37% 28% 0.67 (0.31–1.42); 0.3
Laryngeal tumours
 - DSS 63% 51% 1.62 (0.56–4.7); 0.38
 - OS 52% 43% 1.35 (0.47–3.8); 0.58
Table 2.  Five-year disease-specific survival (DSS) and overall survival (OS) according to ANO1 
expression. HR: hazard ratio; CI: Confidence interval.
Figure 2. Frequencies of ANO1 protein expression and gene amplification in the different stages of 
laryngeal tumourigenesis. 
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Associations with laryngeal cancer risk. We next studied the relationship of ANO1 protein expres-
sion and gene amplification with the risk of developing laryngeal cancer in patients with premalignant 
lesions. Interestingly, we found that ANO1 expression and, particularly, ANO1 gene amplification asso-
ciated with a higher frequency of progression to malignancy (Table  4). Consistent with these results, 
patients carrying lesions with ANO1 gene amplification experienced a higher risk of cancer develop-
ment (Fig. 3; HR = 3.62; 95% CI 0.79–16.57; P = 0.097, Cox regression), compared to patients carrying 
ANO1-positive lesions (HR = 1.65; 95% CI 0.44–6.24; P = 0.46, Cox regression).





 Mild Dysplasia 4 (12) 3 (75) 0
 Moderate Dysplasia 12 (34) 6 (50) 0
 Severe Dysplasia 19 (54) 13 (68) 7 (37)
 Total 35 22 (63) 7 (20)








 Mild dysplasia 4 (12) 0 (0)
0.117 Moderate dysplasia 12 (34) 2 (17)
 Severe dysplasia 19 (54) 9 (47)
ANO1 gene amplification
 Negative 13 (37) 2 (15)
0.139
 Positive 22 (63) 10 (45)
ANO1 protein expression
 Negative 28 (80) 8 (29)
0.652
 Positive 7 (20) 3 (43)
Table 4.  Evolution of the premalignant lesions in relation to histopathologic diagnosis, ANO1 gene 
amplification and protein expression at five years. †Fisher’s exact test.
Figure 3. Cancer-free survival curves categorized by ANO1 gene amplification (positive versus negative) 
in patients with laryngeal premalignancies. 
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Discussion
11q13 amplification is a prevalent genetic alteration in HNSCC, observed in patients with advanced dis-
ease, a poorly differentiated histology of the tumour, and deeply invasive growth3. In concordance with 
the presumed association with progressed disease, the cases with amplification develop more frequently 
recurrences and have an increased risk of tumour-associated death3,8. It has been recently demonstrated 
that ANO1 expression and gene amplification significantly correlated with increased propensity to 
develop distant metastasis in HNSCC patients6. ANO1 has been implicated in various processes rele-
vant to tumour progression and metastasis such as the regulation of cell migration, adhesion and inva-
sion6,7,9–11. On the light of these data, ANO1 gene emerges as a strong candidate to play a role in driving 
11q13 amplification.
Nevertheless, current available information is very limited and controversial regarding the clinical rel-
evance of ANO1 in HNSCC patients. Duvvuri et al.12 reported an association of ANO1 expression with 
decreased survival in HNSCC patients, although using a small sample size n = 34 and non-commercial 
antibodies, detecting ANO1 overexpression in 80% cases. Another study by Ruiz et al.7 reported ANO1 
expression in 8% (19/242 cases) ranging 4–19% depending on the HNSCC site. Despite this low fre-
quency, authors were able to find a correlation of ANO1 with poor prognosis, but it is worth noting that 
patients enrolled were subjected to different treatment regimens.
This prompted us to perform a comprehensive analysis of ANO1 expression and gene amplification 
using a large cohort of 372 homogeneously treated HNSCC patients. We detected ANO1 expression 
in 78 (22%) tumours, whilst ANO1 gene amplification occurred at a higher frequency (58%). A pos-
itive correlation was found between ANO1 protein expression and gene amplification (P = 0.003). All 
ANO1-positive tumours harboured ANO1 gene amplification; however, only one-third of cases with 
gene amplification were concomitantly accompanied by ANO1 overexpression. These results are in good 
agreement to those reported by Ruiz et al.7. However, we did not find an association of ANO1 expres-
sion with poor disease-specific survival, as previously reported. Various factors could contribute to these 
contrasting findings, such as differences in the inclusion criteria (e. g. patients undergoing different 
treatments, pooled HNSCC sites), sample sizes, detection methods and/or antibodies used.
Strikingly, we found important differences on the impact of ANO1 in patient survival depending on 
the anatomic site of the tumours. Thus, patients with ANO1-positive oropharyngeal tumours exhibited 
a significantly improved disease-specific survival, compared to hypopharyngeal and laryngeal tumours. 
These findings were confirmed by repeating IHC analysis using two different anti-ANO1 antibodies. 
HPV status data were available for the whole series. Given the low incidence of HPV in our series (3%, 10 
HPV-positive cases), we can rule out the possible contribution of HPV infection as a confounding factor. 
A recent paper demonstrated that ANO1 expression in HNSCC is epigenetically regulated via promoter 
methylation, and interestingly, ANO1 was proposed as a primary driver of the “grow” or “go” model for 
HNSCC progression13. Thus, increased ANO1 expression may promote tumour growth, whereas decreas-
ing ANO1 expression favours transition from an epithelial to a mesenchymal phenotype and the devel-
opment of metastasis. This could explain the overall better prognosis observed in ANO1-positive patients 
in our series. Therefore, ANO1 emerges as a pleiotropic effector that seems to influence tumour prolif-
eration and metastasis in an opposing way, which likely involves regulation through changes in phos-
phorylation and direct protein-protein interactions such as TMEM16A S970 and Radixin13. It has also 
been recently demonstrated that ANO1 interacts with EGFR and facilitates EGFR-signalling in HNSCC, 
thus revealing ANO1 as a promising target and/or biomarker for EGFR-directed therapy in HNSCC14.
Even though the role of ANO1 expression and gene amplification in tumour progression and met-
astatic dissemination has been investigated in different cancers, including HNSCC, its potential con-
tribution to malignant transformation has not yet been explored in clinical samples. In an attempt to 
accomplish this, ANO1 protein expression and gene amplification were analysed on a set of laryngeal 
precancerous lesions, and molecular data correlated with the risk of progression to invasive carcinoma. 
We observed important differences when comparing the timing and frequency of both ANO1 protein 
expression and gene amplification in the different stages of HNSCC tumourigenesis. ANO1 gene ampli-
fication was detected very early (in mild dysplasias) and at a high frequency that was maintained along 
progression; however, ANO1 protein expression was only found in severe dysplasias/CIS and at a lower 
frequency. More importantly, ANO1 gene amplification but not ANO1 expression correlated almost sig-
nificantly with increased laryngeal cancer risk.
In line with this, we described in a previous report that amplifications of CCND1 and CTTN strongly 
and significantly predict laryngeal cancer development14. Both genes are in close proximity to ANO1 
within 11q13 amplicon. However, we found that CTTN (cortactin) expression, but not CCND1 (cyclin 
D1) expression, significantly predicted cancer risk in both larynx and oral cavity15,16.
We also previously demonstrated that CTTN gene amplification and protein overexpression correlated 
with poor prognosis and reduced patient survival in two large prospective series of HNSCC patients4,17, 
thus reinforcing the central role of CTTN in the 11q13 amplicon and also in disease progression. Hence, 
various genes are frequent targets of amplification within the 11q13 region that could cooperatively con-
tribute to cancer development and progression.
In summary, our findings demonstrate that ANO1 gene amplification occurs frequently in both pre-
malignant lesions and invasive tumours, whereas concomitant ANO1 expression was detected at a much 
lower frequency. This study provides original evidence demonstrating the potential utility of ANO1 gene 
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amplification as a cancer risk marker in patients with laryngeal dysplasia, and also that the prognostic 
significance of ANO1 expression in HNSCC seems to be site-dependent.
Methods
Patients and Tissue Specimens. Surgical tissue specimens from 372 patients with HNSCC who 
underwent resection of their tumours at the Hospital Universitario Central de Asturias between 1990 
and 2009 were retrospectively collected, in accordance to approved institutional review board guide-
lines. All experimental protocols were approved by the Institutional Ethics Committee of the Hospital 
Universitario Central de Asturias. Informed consent was obtained from all patients. Representative tissue 
sections were obtained from archival, paraffin-embedded blocks and the histological diagnosis was con-
firmed by an experienced pathologist (A.A.).
The sections were selected for study as follows: In premalignant lesions, the entire lesion was included 
in one block and therefore the section used for histological diagnosis was subsequently used for DNA/
protein analysis. In carcinomas, three morphologically representative areas were selected from each indi-
vidual tumour paraffin block for the construction of a tissue microarray (TMA), as described previously18.
The premalignant lesions were classified into categories of mild, moderate or severe dysplasia follow-
ing the WHO classification19. Four (12%) lesions were classified as showing mild dysplasia, 12 (34%) as 
moderate dysplasia, and 19 (54%) as severe dysplasia/carcinoma in situ (CIS). All patients with prema-
lignant lesions were men, with a mean age of 66 years (range 43–82 years). All of them were smokers 
and 23 were also habitual alcohol drinkers. Patients with a diagnosis of premalignant lesion and cancer 
within the next 6 months were excluded from the study. All patients were treated by excisional biopsy 
using stripping microflap excision with cold instruments. A complete macroscopic exeresis of the lesion 
was performed in all cases, but the microscopic margins were not addressed. Patients were followed-up 
for a minimum of 60 months or until progression to malignancy occurred.
A large unbiased cohort of 372 homogeneous surgically treated HNSCC patients was selected for 
study. All patients had a single primary tumour, microscopically clear surgical margins and received no 
treatment prior to surgery. Only fourteen patients were women, and the mean age was 59 years (range 
30 to 86 years). All but twelve patients were habitual tobacco smokers, 198 moderate (1–50 pack-year) 
and 153 heavy (> 50 pack-year), and 341 were alcohol drinkers. The stage of the tumours was determined 
according to the TNM system of the International Union Against Cancer (7th Edition): 18 tumours 
were stage I, 24 stage II, 64 stage III, and 266 stage IV. The series included 147 well, 145 moderately and 
79 poorly differentiated tumours, determined according to the degree of differentiation of the tumour 
(Broders’ classification). 232 (62%) of 372 patients received postoperative radiotherapy.
Tissue microarray (TMA) construction and DNA extraction. Five morphologically representative 
areas were selected from each individual tumour paraffin block: two for DNA isolation and three for the 
construction of a TMA. To avoid cross-contamination, two punches of 2 mm diameter were taken first, 
using a new, sterile punch (Kai Europe GmbH, Solingen, Germany) for every tissue block, and stored in 
eppendorf tubes at room temperature. Subsequently, three 1 mm cylinders were taken to construct TMA 
blocks, as described previously18,20, containing a total of 372 HNSCC (140 tonsillar, 108 base of tongue, 
62 hypopharyngeal and 62 laryngeal carcinomas). In addition, each TMA included three cores of normal 
epithelium as an internal negative control. The protocol for DNA extraction from paraffin-embedded 
tissue sections has been described elsewhere9.
Gene Amplification Analysis. Gene amplification was evaluated by Real-time PCR (Q-PCR) 
in an ABI PRISM 7500 Sequence detector (Applied Biosystems, Foster City, CA) using Power SYBR 
Green PCR Master Mix and oligonucleotides designed according to Primer Express software v2.0 
with the following sequences: for ANO1 gene, Fw, 5′ - CAAAGGCAGGTGCTTTGCA -3′ and Rv, 5′ - 
TCTACGGGCCTCTGCTCACT -3′ , and for the reference gene TH (Tyrosine Hydroxylase, located at 
11p15), Fw, 5′ -TGAGATTCGGGCCTTCGA-3′ and Rv, 5′ -GACACGAAGTAGACTGACTGGTACGT-
3′ . Dissociation curve analysis of all PCR products showed a single sharp peak and the correct size of 
each amplified product was confirmed by agarose gel electrophoresis. The relative gene copy number for 
ANO1 was calculated using the 2−ΔΔCT method. The Δ Δ CT represents the difference between the paired 
tissue samples (Δ CT of tumour − Δ CT of normal mucosa), with Δ CT being the average CT for the target 
gene (ANO1) minus the average CT for the reference gene (TH). Values higher than 2.0 were considered 
positive for gene amplification.
Immunohistochemistry. The formalin-fixed, paraffin-embedded tissues were cut into 3-μ m sections 
and dried on Flex IHC microscope slides (Dako). The sections were deparaffinized with standard xylene 
and hydrated through graded alcohols into water. Antigen retrieval was performed using Envision Flex 
Target Retrieval solution, high pH (Dako). Staining was done at room temperature on an automatic 
staining workstation (Dako Autostainer Plus) with rabbit polyclonal Anti-TMEM16A antibody (Abcam 
#ab53212) at 1:500 dilution or with rabbit monoclonal Anti-TMEM16A [SP31] antibody (Abcam 
#ab64085) at 1:100 dilution using the Dako EnVision Flex + Visualization System (Dako Autostainer). 
Counterstaining with haematoxylin for 1 minute was the final step.
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A semiquantitative scoring system based on staining intensity was applied. Immunostaining was 
scored blinded to clinical data by two independent observers as negative (0), weak to moderately (1+ ), 
and strongly positive (2+ ) based on staining intensity. Scores ≥ 1 were considered as ANO1 positive 
expression. Cut-off point was determined by survival.
Statistical Analysis. Fisher’s exact test was used for comparison between categorical variables and 
odds ratios were reported as effect measure. Correlation between gene amplification and protein expres-
sion was tested by Spearman’s correlation coefficient. Due to the presence of competing risk events, 
the disease-specific survival was estimated using the multiple decrement method while the standard 
Kaplan-Meier was used for overall survival. Differences between curves were tested from the log-rank 
method. Hazard ratios and respective 95% confidence intervals, computed from the usual proportional 
hazard Cox model were reported as measure of the effect. All tests were two-sided. P values of ≤ 0.05 
were considered to be statistically significant.
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